Earnings Quality in Focus — ARCIL Posts Q2 Results Amid Cash-Conversion Watch
With six weeks of post-IPO trading behind it, ARCIL reports Q2 earnings as Street scrutinizes whether recovery acceleration and mark-to-market gains are sustainable. Watch operating cash flow recovery and fresh mandate inflows.
ARCIL reported its maiden full-year results post-IPO (Sept 17, 2026 @ ₹139) last quarter, with profit of ₹407.84 Cr and AUM growth of 15% to ₹20,150 Cr. That printed at 11.08x P/E and 1.47x P/B—a modest valuation for a category pioneer. But the Street's focus is narrow: earnings quality. Nearly half of FY26 profits came from mark-to-market gains on security receipts, while operating cash flow collapsed 52% YoY, leaving only 38% cash conversion. Q2 is the first post-IPO print, and it will test whether recovery acceleration and the AUM base are real.
What to Expect
~₹20,500–21,000 Cr
15% run-rate growth implies ₹20,150 Cr base; in-quarter recoveries will reduce this, offset by fresh mandates post-IPO
~50%+
FY26 saw ₹407.84 Cr on ₹815 Cr revenue; Street will dissect how much is MTM vs. cash recovery
~₹150–200 Cr (est.)
H1 FY26 ran ₹153.58 Cr (37.66% of profit). Watch for recovery—key quality metric
~10.5–11% / ~13–13.5%
H1 FY26 posted 11.0% RoA, 13.4% RoNW; trajectory matters for valuation re-rating
Strong quarter: A strong Q2 would show AUM growth holding above 15% YoY (despite natural portfolio paydowns), operating cash conversion recovering to 45%+ of net profit, and management guiding toward stable or improved recovery rates in H2 FY-2027. New mandate inflows post-IPO would be a plus. Weak quarter: Weakness would manifest as slowing AUM growth (below 12% YoY), cash flow remaining depressed (below 40% conversion), or guidance signaling slower recovery rates or sector headwinds (real estate, thermal power, roads remain 50%+ of portfolio).
On Track?
ARCIL has no formal full-year FY-2027 guidance published yet (listing was Sept 17). Management has historically guided 75–80% cumulative recovery rates post-acquisition and steady AUM growth aligned with market share gains. With H1 tracking complete (FY26 close was Mar 31, 2026) and no mid-year update yet, Q2 results will be the first tangible signal of execution post-listing. The 100% OFS structure means no fresh capital for organic expansion—growth must come from new mandate wins and recovery proceeds deployment.
What the Street Says
Since Last Quarter
Trading window closure (Sep 17, Sep 30): Routine insider trading blackout ahead of Q2 results; compliance-driven, no operational signal. Board meeting intimation (Sep 29): Board convenes Oct 6 to approve audited Q2 FY27 results (both standalone and consolidated). UPSI & fair disclosure (Sep 17): Filed updated Code of Practices for fair disclosure of unpublished price-sensitive information; routine regulatory housekeeping post-listing. Bulk/block deals (last 6 months): BNP Paribas Financial Markets bought 28,28,095 shares @ ₹137.47, then sold 86,143 @ ₹134.22—modest positions, no promoter/insider activity flagged.
What to Watch on Oct 6
1 · Operating Cash Flow Recovery
Can ARCIL recover OCF-to-profit conversion from the alarming 37.66% (₹153.58 Cr / ₹407.84 Cr net profit) seen in FY26? Street sees this as the earnings quality bellwether. A recovery toward 45%+ signals sustainable margin; a repeat dip re-ignites MTM-distortion concerns.
2 · Mark-to-Market Composition
Management will need to isolate MTM gains (FY26: ₹195.16 Cr / ₹407.84 Cr = 47.85%) from cash recovery profit. Any reversal of MTM positions or lower realization rates would shake confidence in stated profitability.
3 · AUM Growth & New Mandates Post-IPO
Post-listing momentum—do fresh mandates offset portfolio paydowns? If AUM growth slows below 12% YoY or guidance signals slower mandate inflows, it signals market-share plateau and constrains valuation multiples.
ARCIL is India's category-defining ARC, commanding a 15% AUM CAGR and 50%+ margins over a recovery model built on real estate, thermal power, and roads sector expertise. But the IPO brought scrutiny—Street is paying hard attention to whether earnings are cash-backed or cosmetic. Q2 will be the first litmus test: AUM growth tracking plan, cash conversion improving, and RoA/RoNW sustained. Watch the MTM breakdown and management's comfort on FY-2027 profit guidance. Valuation upside hinges on proof that this 11x P/E is too cheap for a real 15%+ EPS compounder.
Informational and educational content only. Not investment advice.